Sophia Genetics (Sophia Genetics) FCF Margin % : -100.11% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sophia Genetics's Free Cash Flow for the three months ended in Mar. 2024 was $-15.80 Mil. Sophia Genetics's Revenue for the three months ended in Mar. 2024 was $15.78 Mil. Therefore, Sophia Genetics's FCF Margin % for the quarter that ended in Mar. 2024 was -100.11%.

As of today, Sophia Genetics's current FCF Yield % is -19.02%.

The historical rank and industry rank for Sophia Genetics's FCF Margin % or its related term are showing as below:

SOPH' s FCF Margin % Range Over the Past 10 Years
Min: -169.21 Med: -136.87 Max: -88.93
Current: -88.93

During the past 6 years, the highest FCF Margin % of Sophia Genetics was -88.93%. The lowest was -169.21%. And the median was -136.87%.

SOPH's FCF Margin % is ranked worse than
90.81% of 664 companies
in the Healthcare Providers & Services industry
Industry Median: 1.44 vs SOPH: -88.93

Sophia Genetics FCF Margin % Historical Data

The historical data trend for Sophia Genetics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics FCF Margin % Chart

Sophia Genetics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-136.87

-123.01

-159.73

-169.21

-92.67

Sophia Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial													-118.26	-89.50	-87.54	-79.43	-100.11

Competitive Comparison of Sophia Genetics's FCF Margin %

For the Health Information Services subindustry, Sophia Genetics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sophia Genetics's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sophia Genetics's FCF Margin % falls into.

Sophia Genetics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sophia Genetics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-57.801	/	62.371
	=	-92.67 %

Sophia Genetics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-15.797	/	15.779
	=	-100.11 %

Sophia Genetics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sophia Genetics (Sophia Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

90B:Germany

Address

Rue du Centre 172, Saint-Sulpice, CHE, CH-1025

Website

https://www.sophiagenetics.com

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.